trending Market Intelligence /marketintelligence/en/news-insights/trending/Yuo1ugpNgsTQGUmkpKhsOg2 content esgSubNav
In This List

Translate Bio prices $90M common stock offering

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Translate Bio prices $90M common stock offering

Translate Bio Inc. priced its public offering of 9 million common shares at $10 each.

The Lexington, Mass.-based company, which develops therapies for genetic disorders, also granted underwriters a 30-day option to buy up to an additional 1,350,000 shares at the same price.

The company expects $90 million in gross proceeds from the offering.

Citigroup, Jefferies and SVB Leerink are acting as joint book-running managers for the offer.

Earlier, Translate Bio said it was discontinuing development of its experimental genetic disorder drug MRT5201 and prioritizing its lung disease programs. The biotechnology company was developing MRT5201 to treat ornithine transcarbamylase deficiency, a genetic disorder that allows ammonia to accumulate in the blood.